PDL1 Expression in Cancer (PECan Study).
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Melanoma
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Using [99mTc]-labeled anti-PDL1 single-domain antibody, this study aims to prospectively measure changes in PD-L1 expression determined with SPECT imaging and correlate these changes with response to anti-PD(L)1 immunotherapy.
Using [99mTc]-labeled anti-PDL1 single-domain antibody, this study aims to prospectively measure changes in PD-L1 expression determined with SPECT imaging and correlate these changes with response to anti-PD(L)1 immunotherapy.
Tracking Information
- NCT #
- NCT04436406
- Collaborators
- NanoMab
- Investigators
- Principal Investigator: Gary JR Cook King's College London, London, UK
Get Well Soon